Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.34 |
| ▸ | SMO | Q99835 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA4 | P22748 | 4/20 | 0.34 |
| ▸ | CA7 | P43166 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22976844 | 1.00 | SMPD3 (0.35) | SMPD3BTKSSTR2SMOCA12 | |
| SCHEMBL22976537 | 0.87 | SSTR2 (0.38) | SMPD3BTKSSTR2 | |
| SCHEMBL22976533 | 0.87 | SSTR2 (0.38) | SMPD3BTKSSTR2 | |
| SCHEMBL29720136 | 0.87 | SSTR2 (0.38) | SMPD3BTKSSTR2 | |
| SCHEMBL29653510 | 0.86 | JAK3 (0.45) | BTK | |
| SCHEMBL29106948 | 0.82 | SSTR2 (0.46) | SSTR2 | |
| SCHEMBL22976543 | 0.81 | AURKA (0.37) | SMPD3BTKCA12CA1CA2 | |
| SCHEMBL22976542 | 0.81 | AURKA (0.37) | SMPD3BTKCA12CA1CA2 | |
| SCHEMBL28777695 | 0.80 | SSTR2 (0.35) | SSTR2 | |
| SCHEMBL28777696 | 0.80 | SSTR2 (0.35) | SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294797-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | Crinetics Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11773076-B2 | Crystalline forms of a somatostatin modulator | Crinetics Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2022177974-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | Crinetics Pharmaceuticals, Inc. (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-4013748-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-05-12 | — | — | US | disclosed |
| WO-2021030262-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | SMPD3 312/4885BTK 3435/4885SSTR2 4/4885 |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | SMPD3 312/4885BTK 3435/4885SSTR2 4/4885 |
| US-11773076-B2 | Crystalline forms of a somatostatin modulator | SSTR5, SSTR3, SSTR4 | SMPD3 665/4885BTK 4519/4885SSTR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.